loxapine has been researched along with Basal Ganglia Diseases in 15 studies
Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Using an optimizing dosage regime, the outcome variables studied were aggression frequency and the number and nature of emergent side effects." | 6.67 | Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. ( Ancill, RJ; Carlyle, W; Sheldon, L, 1993) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 5.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| "This study compared the therapeutic efficacy of thioridazine, loxapine, and a placebo in the treatment of behavioral disturbances in nursing home patients with dementia." | 3.66 | Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. ( Barnes, R; Gumbrecht, G; Okimoto, J; Raskind, M; Veith, R, 1982) |
| " Using an optimizing dosage regime, the outcome variables studied were aggression frequency and the number and nature of emergent side effects." | 2.67 | Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. ( Ancill, RJ; Carlyle, W; Sheldon, L, 1993) |
| "Loxapine is a typical neuroleptic that shows great structural and functional homology to the atypical antipsychotic clozapine." | 1.29 | A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. ( Barlas, C; Franks, P; Mishra, RK; Singh, AN; Singh, S, 1996) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 1.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (80.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuason, VB | 1 |
| Escobar, JI | 1 |
| Garvey, M | 1 |
| Schiele, B | 1 |
| Irwin, GE | 1 |
| Simon, JE | 1 |
| Genís Batlle, D | 1 |
| Rubio Goday, M | 1 |
| González López, JL | 1 |
| Macía Martorell, R | 1 |
| Alvarez Villuendas, A | 1 |
| Sala Montero, J | 1 |
| Amado Tobía, JB | 1 |
| Ewert, AL | 1 |
| Kloek, J | 1 |
| Wells, B | 1 |
| Phelps, S | 1 |
| Barnes, R | 1 |
| Veith, R | 1 |
| Okimoto, J | 1 |
| Raskind, M | 1 |
| Gumbrecht, G | 1 |
| Carlyle, W | 1 |
| Ancill, RJ | 1 |
| Sheldon, L | 1 |
| Singh, AN | 1 |
| Barlas, C | 1 |
| Singh, S | 1 |
| Franks, P | 1 |
| Mishra, RK | 1 |
| Glazer, WM | 1 |
| Cottereau, MJ | 1 |
| Poirier, MF | 1 |
| Lôo, H | 1 |
| Deniker, P | 1 |
| Ayd, FJ | 1 |
| Mattke, DJ | 1 |
| Mombour, W | 1 |
| Glötzner, FL | 1 |
| Fruensgaard, K | 1 |
| Jensen, K | 1 |
| Simpson, GM | 1 |
| Branchey, MH | 1 |
| Lee, JH | 1 |
| Varga, E | 1 |
| Rosse, RB | 1 |
| Theut, SK | 1 |
| Banay-Schwartz, M | 1 |
| Leighton, M | 1 |
| Scarcella, E | 1 |
| Cohen, CG | 1 |
| Deutsch, SI | 1 |
2 reviews available for loxapine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Does loxapine have "atypical" properties? Clinical evidence.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Hu | 1999 |
Loxapine update: 1966-1976.
Topics: Acute Disease; Administration, Oral; Age Factors; Ambulatory Care; Antiparkinson Agents; Basal Gangl | 1977 |
4 trials available for loxapine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study.
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Dibenzoxazepines; Dizziness | 1984 |
Aggression in the demented patient: a double-blind study of loxapine versus haloperidol.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Basal Ganglia Diseases; Dementia; Dementia, | 1993 |
[The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research (author's transl)].
Topics: Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Dibenzoxazepines; Female; Haloperidol; Huma | 1975 |
Loxapine (Loxitane).
Topics: Acute Disease; Basal Ganglia Diseases; Clinical Trials as Topic; Dibenzoxazepines; Humans; Loxapine; | 1975 |
9 other studies available for loxapine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Neuroleptic malignant syndrome.
Topics: Basal Ganglia Diseases; Chronic Disease; Diagnosis, Differential; Dibenzoxazepines; Dose-Response Re | 1984 |
[Malignant syndrome caused by neuroleptics. A case produced by loxapine].
Topics: Basal Ganglia Diseases; Dibenzoxazepines; Humans; Loxapine; Male; Malignant Hyperthermia; Middle Age | 1984 |
Neuroleptic malignant syndrome associated with loxapine.
Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Dibenzoxazepines; Female; Fever; Humans; Loxapine | 1983 |
Efficacy of antipsychotic medications in behaviorally disturbed dementia patients.
Topics: Aged; Basal Ganglia Diseases; Dementia; Dibenzoxazepines; Double-Blind Method; Female; Humans; Hypot | 1982 |
A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Binding Sites; Cerebral Cortex; Culture Techniques; Hu | 1996 |
[Loxapine succinate: a new neuroleptic].
Topics: Adult; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Chronic Disease; Dibenzoxazepines; Dr | 1979 |
Treatment of acute psychotic patients with loxapine parenterally.
Topics: Acute Disease; Basal Ganglia Diseases; Dibenzoxazepines; Female; Humans; Injections, Intramuscular; | 1976 |
A two year trial of loxapine succinate in chronic psychotic patients.
Topics: Adult; Basal Ganglia Diseases; Blood Pressure; Body Weight; Chronic Disease; Dibenzoxazepines; Femal | 1976 |
Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Basal Ganglia Diseases; Benztropine; Chronic Disease; Cognitio | 1989 |